Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Similar articles for PubMed (Select 12538861)


Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma.

Charest A, Kheifets V, Park J, Lane K, McMahon K, Nutt CL, Housman D.

Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):916-21. Epub 2003 Jan 21.


Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21).

Charest A, Lane K, McMahon K, Park J, Preisinger E, Conroy H, Housman D.

Genes Chromosomes Cancer. 2003 May;37(1):58-71.


ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice.

Charest A, Wilker EW, McLaughlin ME, Lane K, Gowda R, Coven S, McMahon K, Kovach S, Feng Y, Yaffe MB, Jacks T, Housman D.

Cancer Res. 2006 Aug 1;66(15):7473-81.


Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein.

Peschard P, Fournier TM, Lamorte L, Naujokas MA, Band H, Langdon WY, Park M.

Mol Cell. 2001 Nov;8(5):995-1004.


Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation.

Zeng L, Sachdev P, Yan L, Chan JL, Trenkle T, McClelland M, Welsh J, Wang LH.

Mol Cell Biol. 2000 Dec;20(24):9212-24.


Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis.

Porter AC, Vaillancourt RR.

Oncogene. 1998 Sep 17;17(11 Reviews):1343-52. Review.


Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).

Murata K, Kumagai H, Kawashima T, Tamitsu K, Irie M, Nakajima H, Suzu S, Shibuya M, Kamihira S, Nosaka T, Asano S, Kitamura T.

J Biol Chem. 2003 Aug 29;278(35):32892-8. Epub 2003 Jun 18.


Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.

Drosten M, Hilken G, Böckmann M, Rödicker F, Mise N, Cranston AN, Dahmen U, Ponder BA, Pützer BM.

J Natl Cancer Inst. 2004 Aug 18;96(16):1231-9.


Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A.

Bongarzone I, Monzini N, Borrello MG, Carcano C, Ferraresi G, Arighi E, Mondellini P, Della Porta G, Pierotti MA.

Mol Cell Biol. 1993 Jan;13(1):358-66.


Visualization of SHP-1-target interaction.

Biskup C, Böhmer A, Pusch R, Kelbauskas L, Gorshokov A, Majoul I, Lindenau J, Benndorf K, Böhmer FD.

J Cell Sci. 2004 Oct 1;117(Pt 21):5165-78.


Ret oncogene signal transduction via a IRS-2/PI 3-kinase/PKB and a SHC/Grb-2 dependent pathway: possible implication for transforming activity in NIH3T3 cells.

Hennige AM, Lammers R, Arlt D, Höppner W, Strack V, Niederfellner G, Seif FJ, Häring HU, Kellerer M.

Mol Cell Endocrinol. 2000 Sep 25;167(1-2):69-76.


Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.

Xie S, Wang Y, Liu J, Sun T, Wilson MB, Smithgall TE, Arlinghaus RB.

Oncogene. 2001 Sep 27;20(43):6188-95.


Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.

Melillo RM, Santoro M, Ong SH, Billaud M, Fusco A, Hadari YR, Schlessinger J, Lax I.

Mol Cell Biol. 2001 Jul;21(13):4177-87.


Oncogenic activation of the tyrosine kinase domain of the human trk proto-oncogene by fusion to a cell adhesion molecule.

Albor A, Thraves PJ, Dritschilo A, Notario V.

Oncogene. 1996 Oct 17;13(8):1755-63.


The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3 oncoprotein to the plasma membrane.

Monaco C, Visconti R, Barone MV, Pierantoni GM, Berlingieri MT, De Lorenzo C, Mineo A, Vecchio G, Fusco A, Santoro M.

Oncogene. 2001 Feb 1;20(5):599-608.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk